Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening
Clinical Gastroenterology and Hepatology · 2025-11 · 23 (12) · 2328-2338.e9
DOI: 10.1016/j.cgh.2025.03.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-11. Verfasst von Satoko Ito und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Colorectal Neoplasms, Hereditary Nonpolyposis, Early Detection of Cancer, Colorectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NOMIS Stiftung.
Abstract (Originalsprache)
BACKGROUND & AIMS: Testing all colorectal cancers (CRCs) for mismatch repair status to evaluate for Lynch syndrome (LS) has been recommended for years. Owing to attrition in the multistep diagnostic testing pathway, most qualifying patients still do not receive genetic testing for LS. This leads to missed diagnoses and preventable cancer incidence. To tackle this, we previously reported a systems approach that resulted in a dramatic increase in the identification of patients with LS. We aim to evaluate the cost-effectiveness of this intervention compared with both real-world pre-intervention experience and with upfront germline testing of all CRC probands. METHODS: We employed data from the Prospective Lynch Syndrome Database, the National Cancer Institute Surveillance, Epidemiology, and End Results program, and pre-/post-intervention cohort studies to build lifetime Markov cohorts of CRC probands, testing 3 strategies: (1) current standard-of-care; (2) optimized standard-of-care; and (3) upfront germline testing. The primary outcome was the incremental cost-effectiveness ratio (ICER) in $ per quality-adjusted life-year (QALY) from the United States health system perspective. RESULTS: Strategies #1 to #3 accrued 11.97, 11.98, and 11.99 discounted QALYs at discounted costs of $100,610, $100,980, and $102,290, respectively. The pairwise ICERs on the frontier were $34,500/QALY (95% credible interval [CI], $28,400-$44,200) and $98,500/QALY (95% CI, $73,700-$216,000), respectively. The cost-effectiveness of #3 vs #1 was $70,300/QALY (95% CI, $54,600-$92,500). Current standard-of-care was favored in 0.0% of 10,000 Monte Carlo iterations. CONCLUSIONS: Current clinical practice is cost-ineffective. Prospective intervention to dramatically increase LS testing (ie, to reach a threshold of >75%) or, if this level cannot be reached, upfront germline testing are cost-effective interventions that improve quality-adjusted life expectancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut.
- Department of Genetics, Yale School of Medicine, New Haven, Connecticut.
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
- Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- NOMIS Stiftung
- Frederick A. DeLuca Foundation
- NHLBI
- Yale Cancer Center
- National Institutes of Health
- NCI
Zitieren
APA
Ito, S., Xicola, R. M., Sra, M., Potnis, K. C., Singh, V., Gershkovich, P., Stites, E., Gibson, J., Krumholz, H. M., Llor, X., & Goshua, G. (2025). Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clinical Gastroenterology and Hepatology, 23(12), 2328-2338.e9. https://doi.org/10.1016/j.cgh.2025.03.006
Vancouver
Ito S, Xicola RM, Sra M, Potnis KC, Singh V, Gershkovich P, et al. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clinical Gastroenterology and Hepatology. 2025;23(12):2328-2338.e9. doi:10.1016/j.cgh.2025.03.006
BibTeX
@article{Ito2025,
author = {Ito, Satoko and Xicola, Rosa M and Sra, Manraj and Potnis, Kunal C and Singh, Vinit and Gershkovich, Peter and Stites, Edward and Gibson, Joanna and Krumholz, Harlan M and Llor, Xavier and Goshua, George},
title = {Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
volume = {23},
number = {12},
pages = {2328--2338.e9},
doi = {10.1016/j.cgh.2025.03.006}
}
EUVIMED